edit-401
edit-401: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Editas Medicine, Inc. (EDIT) | Phase 1 |
FDA Decisions
FDA_MeetingFeedback received on nonclinical package, CMC plans, and study design to support an IND, providing optionality for clinical development strategy.(EDIT)
Frequently asked questions
Who is developing edit-401?
edit-401 is being developed by Editas Medicine, Inc..
What is edit-401's latest FDA decision?
The most recent tracked FDA decision for edit-401 is FDA_Meeting for Feedback received on nonclinical package, CMC plans, and study design to support an IND, providing optionality for clinical development strategy..
Get deeper analysis on edit-401
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis